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Abstract: Leishmania major is an intracellular parasite generally responsible for cutaneous leishmaniasis (CL), one of the most encountered skin diseases 
especially in Pakistan, Iran, Iraq, and Saudi Arabia. Current treatment options are not ideal, due to unwanted side effects and increasing resistance and availability 
is often limited in developing countries. Medicinal plants continue to attract attention because of their beneficial effects in the prevention or/and accelerating the 
healing process of various diseases. In this study, in vitro and in vivo susceptibility of L. major to Veronica persica Poir. extract, a medicinal plant with many 
applications, has been evaluated. Antileishmanial activity of plant extract was investigated both on cultured L. major promastigotes and in mice challenged with 
L. major. Animals were divided into three groups including control (without any treatment), test (treated with plant extract) and glucantime (the reference drug) 
treated groups. After treatments, skin lesion sizes and body weights of animals were checked during 4 weeks. The potential of the plant extract in decreasing the 
number of parasites in spleen cells of animals as well as inducing the nitric oxide (NO) production by macrophage cells was also investigated. In vitro tests showed 
that the plant extract was able to reduce the survival time of promastigotes in a concentration-dependent manner. In vivo experiments also revealed a significant 
influence of V. persica extracts on accelerating the healing process as well as reducing the overall disease burden in animal model by inducing NO production in 
macrophage cells. Our findings indicated the promising potential of V. persica extract as an ideal candidate in the treatment of CL caused by L. major.
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Introduction
Leishmania major is an intracellular parasite res-
ponsible for human cutaneous leishmaniasis mostly 
recurring in Asia and Africa (1-3). In the life cycle, 
rodents and sand fly sequentially acts as the hosts and 
the vector of this pathogen (4-6). The main targets of L. 
major in the human body are dendritic cells and macro-
phages, which are two central agents of the immune 
system. After the Leishmania promastigotes enter the 
dermis, the responsibility of macrophages is to collect 
them from the environment before they can interact 
with intracellular matrix (7, 8). However, it is known 
that the entrance of promastigotes is an active process 
by their attachments to several receptors on macrophage 
cells. The cycle then continues after division and trans-
formation of promastigotes into amastigotes, which can 
be phagocytosed again or transferred to sand fly vectors 
during feeding. The manifestation of this process is for-
ming nodules and lesions on the place of the sandfly bite 
on the skin (9, 10). The cutaneous lesions can be small 
and self-healing or they can be severe lesions with no 
chance of healing (11). 
The high incidence rate of leishmaniasis (1.5–2 mil-
lion cases per year) has led to great efforts by many 
scientists to overcome this problem (12, 13). In deve-
loping countries, medicinal plants have received much 
attention because of their beneficial effects on the pre-
vention or/and acceleration of the healing process of 
various diseases (14-18). Compared to common thera-
pies which can lead to serious side effects and provide 
a time-consuming healing process, these plants can be 
ideal candidates with low prices and safe profiles in 
many situations (15, 19-31). 
In this context, Veronica species are known as an 
effective traditional treatment with huge applications 
from wound healing to anti-cancer and anti-rheumatic 
activities (9, 32, 33). Veronica persica Poir. (also known 
as bird's-eye speedwell, common field-speedwell, Per-
sian speedwell, large field speedwell, bird's-eye, or win-
ter speedwell) from the Plantaginaceae family is one of 
the widespread Veronica species in Eurasia and eastern 
Asia (34-36). As with other Veronica species with a pro-
mising medical perspective, the investigation of V. per-
sica therapeutic effects would be of utmost relevance. 
The aim of this study was to assess the susceptibility of 
L. major to V. persica extract in both in vitro and in vivo 
conditions. As far as we know, there is no information 
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regarding the therapeutic potential of V. persica in the 
treatment of cutaneous leishmaniasis.
Materials and Methods
Preparation of plants 
Aerial parts (stems, leaves, and flowers) of Vero-
nica persica Poir. were collected during the flowering 
period, April 2016, from wild plants in the mountains of 
Meymand, Firuzabad County, Fars Province, Iran. The 
plant was taxonomically identified by a botanist at the 
herbarium of the Zabol University of Iran. Plant parts 
were air-dried in the shade at ambient temperature (18-
25 °C) for 3 days. The crude extracts were obtained by 
maceration of dried aerial parts (100 g) to which 100 
mL methanol was added in a dark place at room tempe-
rature. The pure extracts were filtered (Whatman No. 2 
filter paper), and the solvent removed from the filtrate 
under reduced pressure (rotary evaporator) at 35 °C. 
The concentrated extracts so obtained were then stored 
at -20 °C in labeled sterile bottles and kept until further 
evaluation. The extract concentrations were made based 
on dry weight of extract/volume.
Culture of parasite
The Iranian strain of Leishmania major MRHO/
IR/75/ER was used in this study. The parasite was 
cultured in Novy-MacNeal-Nicolle medium (Sigma-
Aldrich Co., St. Louis, MO, USA) before being mass 
produced in RPMI-1640 (Sigma-Aldrich Co., St. Louis, 
MO, USA) containing 4.5 mg/mL glucose, 10% fetal 
bovine serum and 292 mg/mL L-glutamine as well as 
100 IU/mL penicillin and 100 mg/mL streptomycin for 
decontamination of bacteria. The cultures were incuba-
ted at 25 ºC and the stationary phase of parasite growth 
was obtained after one week, they and used within 2 
weeks post-incubation (37).
In vitro assays
The anti-leishmanial activity of V. persica extract 
was tested on late log phase of L. major promastigotes 
inoculated in RPMI-1640 medium (Sigma-Aldrich Co., 
St. Louis, MO, USA) supplemented with 10% fetal calf 
serum at 106 parasites/mL (38). The viability of parasites 
was evaluated in triplicate against different concentra-
tions of 10, 50, 100, 150, 300, 500, 750, and 1000 μg/
mL plant extracts. The viable promastigotes were then 
counted after 24, 48, and 72 h incubation period at 25ºC 
using a Neubauer chamber. The concentration of the 
extract able of inhibiting 50% of parasite growth (IC50) 
was calculated. In this test, glucantime was used as a 
positive control for each set of experiments.
Extract-based ointment preparation 
In this study, the extract-based ointment was prepa-
red as per the following formulation: dried plant extract 
(20%) was added to lanolin (10%) (to enhance the hy-
drophilicity of the preparation) and dimethyl sulfoxide 
(DMSO 12%, as penetration enhancer and was used to 
improve the drug absorption through the skin) before 
being integrated in soft paraffin (as a greasy ointment 
base to incorporate the abovementioned materials) (38). 
For the preparation of extract-based ointment, preserva-
tives were not added and the ointment was stored at 4 ºC 
and used within 3 days after preparation.
In vivo assays
All animal manipulations were carried out according 
to the Helsinki Convention. The protocol study received 
the approval from Ethics Shahid Beheshti University of 
Medical Sciences, Tehran, Iran (Approval code num-
ber: IR.SBMU.RETECH.REC.1396.586). The female 
BALB/c mice, aged 4–5 weeks and weighed 25–40 g, 
were obtained from Razi Vaccine and Serum Research 
Institute (Karaj, Iran), kept in stainless-steel cages in 
a well-ventilated room and allowed to adapt to their 
controlled environmental conditions (25 ± 3.5 ºC and 
12:12 hours light-dark cycle) before and during the ex-
periments. Animals had free access to food and water. 
Twenty-one mice randomly divided into 3 groups (N = 
7) were used for the assay. An inoculum of Leishmania 
promastigotes (106) at stationary phase was intradermal-
ly injected in the tail base of each mouse. The groups 
of mice included the test groups, which received glu-
cantime (gold standard) or the plant extract (1000 µg/
mL), and the control group which received either the 
ointment vehicle without plant extract. After one mon-
th, the inoculated mice developed nodules and ulcers. 
Then, the infected mice were treated by applying the 
preparation twice daily at the ulcer site for 4 weeks. The 
concentration of 250 mg of each ointment was weighed 
and applied by a cotton applicator for each mouse on 
each day. Also, the glucantime at 25 mg/kg/day was 
injected intramuscularly. The lesions diameters of the 
treated mice were measured by Kulis Vernier, and were 
then weighed by a digital scale at weekly intervals (38). 
The mice were followed up for 30 days following the 
treatment.
Determination of parasite burden 
In order to determine the parasite burden, three 
mice from each group were sacrificed after one mon-
th of treatment to obtain spleen samples. Then, spleen 
samples were aseptically weighed and homogenized in 3 
mL of Schneider's Drosophila medium (Sigma-Aldrich 
Co., St. Louis, MO, USA) including 0.1% gentamicin 
and 20% heat-inactivated fetal calf serum. Under sterile 
conditions, the homogenates were subjected to serial di-
lutions (1.0-1.4 × 10−4) in 96-well tissue culture plates. 
The plates were incubated at 25 ºC and evaluated for 
mobile promastigotes for 5 to 20-day post-incubation 
using an inverted microscope at 40× magnification. The 
parasite burden (cells/g tissue) was calculated by fol-
lowing the formula (39):
Parasite burden = -log10 (Parasite dilution/Tissue 
weight) 
Nitrite levels determination 
The Griess reaction assay was used to determine 
nitrite levels (40). The peritoneal macrophages were 
harvested from mice exposed to plant extract (1000 µg/
mL), glucantime, and from untreated mice. The har-
vested macrophages were cultured in the flask before 
the adherent cells were removed by gentle scraping and 
washed with warm medium (25± 2.5 ºC). Then, the 
macrophages were counted and their viability was de-
termined. The viable cells were additionally cultured in 
24-well plates before incubation in 5% CO2 at 37 ºC for 
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1000 µg/mL plant extract) and the control groups (P < 
0.05); however, during the next weeks, the weight of 
animals remained stable with a slight decrease in the test 
and glucantime groups. Conversely, animals in control 
group suffered from a remarkable decrease in their body 
weights (P < 0.05) (Table 1).
The lesion sizes (mm) increased over time in the 
three groups; however, the lesion growth rate was lower 
for the groups treated with plant extract and glucantime 
and faster for the control group. In the fourth week, the 
lesion sizes were around 1.94 ± 0.81, 1.99 ± 0.11 and 
2.56 ± 0.65 mm for the plant extract, glucantime and 
control groups, respectively (Table 2).
After counting the parasites in spleen cells, a reduced 
20 h. After the removal of non-adherent cells, the plant 
extracts were added to wells either with or without 0.2 
mmol/L L-NG-monomethyl arginine as nitrite synthase 
inhibitor. After 48 h, the supernatants were collected 
and nitrite accumulation was evaluated.
Statistical analysis
Data obtained were subjected to analysis of variance 
(ANOVA) following a completely random design to 
determine the least significant difference (LSD) at P < 
0.05 by SPSS v. 11.5. All assays were carried out in tri-
plicate.
Results
After exposure of L. major promastigotes to the plant 
extract and glucantime in different concentrations and 
time intervals (24, 48, and 72 h), a dose-dependent and 
significant decrease was observed in survival time of the 
promastigotes compared to the control group (P < 0.05) 
(Figures 1-3). In addition, a decrease in promastigote 
survival time was observed after 72 h exposure with 
the same concentrations of plant extract and glucantime 
when compared to other time intervals (24 and 48 h).
In vivo inhibitory effects of plant extract in pro-
mastigote-inoculated mouse models were assessed by 
measuring the mouse weights and lesion sizes in dif-
ferent weeks. In the first week, there was no difference 
between mouse body weights in the test (treated with 
Figure 1. The Leshmania major promastigote viability after 24 
h exposure to Veronica persica extract or glucantime (positive 
control). Control: untreated promastigotes.
Figure 3. The Leishmania major promastigotes viability after 72 
h exposure to Veronica persica extract or glucantime (positive 
control). Control: untreated promastigotes.
Time Plant extract (1000 µg/mL) Glucantime (25 mg/kg/day) Control
First week 19.34 ± 0.54 Aa 19.25 ± 0.24 Aa 19.42 ± 0.11 Aa
Second week 19.32 ± 0.93 Aa 19.22 ± 0.44 Aa 18.55 ± 0.52 Bb
Third week 19.29 ± 0.11 Aa 19.18 ±0.72 Aa 14.32 ± 0.78 Bc
Forth week 19.24 ± 0.22 Aa 19.15 ± 0.92 Aa 12.22 ± 1.22 Bd
Note: Values are expressed as mean ± SD. The values with different capital letters within a row are significantly different among different groups 
(P < 0.05; LSD). The values with different lower-case letters within a column are significantly different among different weeks (P < 0.05; LSD).
Table 1. The mouse weights (g) in the test (plant extract and glucantime) and control group.
Time Plant extract (1000 µg/mL) Glucantime (25 mg/kg/day) Control
First week 1.44 ± 0.33 Aa 1.62 ± 0.94 Aa 1.42 ± 0.43 Aa
Second week 1.42 ±0.42 Aa 1.73 ± 0.45 Aa 1.95 ± 0.22 Aa
Third week 1.79 ± 0.63 Aa 1.81 ± 0.32 Aa 2.32 ± 0.16 Bb
Forth week 1.94 ± 0.81 Aa 1.99 ± 0.11 Aa 2.56 ± 0.65 Bb
Figure 2. The Leishmania major promastigote viability after 48 
h exposure to Veronica persica extract or glucantime (positive 
control). Control: untreated promastigotes.
Note: Values are expressed as mean ± SD. The values with different capital letters within a row are significantly different among different groups 
(P < 0.05; LSD). The values with different lower letters within a column are significantly different among different weeks (P < 0.05; LSD).
Table 2. The lesion sizes (mm) in the test (plant extract and glucantime) and control group.
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number of parasites was observed in the test groups 
when compared to the control group. The mean number 
of parasites (per mg of spleen tissue) in the plant extract 
(1000 µg/mL), glucantime and control groups were 6.11 
± 0.01, 5.99 ± 2.8 and 9.1 ± 0.7, respectively. 
Nitric oxide (NO) level determination in the three 
groups showed an increased NO production by plant 
extract (1000 µg/mL) ointment and glucantime treat-
ments. The NO levels in plant extract, glucantime and 
control groups were 8.7 µg/mL, 8.1 µg/mL and 4.4 µg/
mL, respectively.
Discussion
About 350 million people are living in the area 
where leishmaniasis occurs (41). With about 1.5 to 2 
million new cases per year, leishmaniasis is one of the 
notable medical problems in the affected regions (41, 
42). The disease is caused by parasitic protozoa that are 
transmitted by sandflies. L. major, L. infantum, and L. 
braziliensis are three known species of this protozoa 
(43). Among these species, L. major is generally res-
ponsible for cutaneous leishmaniosis (CL) which is 
considered as the most encountered form of the disease 
especially in Pakistan, Iran, Iraq and Saudi Arabia (44). 
Despite many advances and achievements in the medi-
cal area, unfortunately, still there is no best treatment for 
the CL. Some chemotherapies plus surgical approaches 
have been suggested for treatment of CL. For instance, 
it has been reported that fluconazole can be used in CL 
patients for accelerating the healing process (45-47). 
However, chemotherapies can bring adversity to pa-
tients because of their various side effects. On the other 
side, resistance of the parasite to chemotherapeutics 
can make this problem more complicated. Nowadays, 
there is a growing interest in the application of natural 
products, especially plant extracts, as an ideal treatment 
choice in various situations (14-17, 24, 25, 48-60). In 
accordance with this, various investigations have been 
carried out to examine the probable effects of different 
plant extracts as a treatment option for leishmaniasis. 
For instance, in one experiment, effects of three plant 
extracts (Hyssopus officinalis, Tussilago farfara, Ca-
rum copticum) were evaluated on mouse models treated 
with L. major (39). Findings of this experiment revea-
led remarkable influence of all three extracts on redu-
cing the lesion sizes and parasite load in the spleens of 
these animals. In another experiment, applying yarrow 
(Achillea millefolium) and thyme (Thymus vulgaris) 
extracts in leishmanial animal models exhibited a signi-
ficant reduction in mean of ulcer sizes when compared 
with control groups (61). In vitro and in vivo effects of 
Peganum harmala on L. major were checked by another 
research team (37). In vitro results showed that the plant 
extract is able to reduce parasite count in a concentra-
tion-dependent manner (IC50 = 59.4 mg/ml). Results of 
in vivo assay also exhibited a significant influence of 
plant extract in reducing the parasite count and lesion 
sizes in tested animals (37).
Our study was designed to check the therapeutic 
activity of V. persica as a medicinal plant for treatment 
of CL. In particular, in vitro and in vivo sensitivity of 
L. major to various concentrations of V. persica ex-
tracts was investigated. In vitro assays showed a high 
and dose-dependent inhibitory activity of the plant 
extract on L. major promastigote survival time. Based 
on our findings, over three time intervals, increasing 
the concentration of plant extract reduced the survi-
val time of the promastigotes. However, a significant 
result was observed after 72 h exposure time, where 
the survival time of promastigotes decreased to 10 % 
by concentration of 750 μg/ml. In addition, compared 
to other exposure times, after 72 h, comparable effects 
were observed by the extracts and glucantime, especial-
ly in concentrations higher than 150 μg/mL. Measuring 
the body weights of the mice in three different groups, 
including controls, treated with plant extract and glu-
cantime, was performed in different weeks. Although, 
in the first week, no significant effect was observed in 
the test group, in following weeks, our observations 
revealed a slight weight loss in this group. Similar re-
sults were observed in glucantime treated group. On the 
other hand, the weight loss in animals of control group 
was remarkable, as expected. In the control group, the 
body weight of animals decreased gradually from the 
first week until the fourth week. The lesion sizes in the 
control group also were significantly different than in 
treated groups with plant extract and glucantime. Infec-
ted animals that received plant extract-based ointment, 
showed a lower progression in lesion size when compa-
red to the control group. Such results showed the poten-
tial of V. persica extract as active agent in reducing the 
lesion development by L. major. Counting the number 
of parasites in spleen cells also revealed the inhibitory 
effects of plant extract, which can ultimately result in 
reducing the burden of disease. Although the number of 
parasites was remarkably higher in the control group, 
there was a reduced amount of parasites in both plant 
extract and glucantime treated groups. Further evalua-
tions to assess the effects of the V. persica extract on 
NO production of macrophages revealed a similar result 
with both V. persica extract and glucantime. Despite a 
lower NO production in the control group, there was 
an increase in NO production in both plant extract and 
glucantime treated groups. These findings indicated the 
promising potential of V. persica extracts to induce NO 
production by macrophage cells. These findings are in 
agreement with above-mentioned reports where various 
plant extracts were tested to find a therapeutic activity 
against leishmanial infections. Indeed, we demonstrated 
the V. persica extract as a potential effective therapeu-
tic agent in reducing the lesion diameter in CL animal 
model. In addition, compared to the control group, this 
extract showed an ability to decrease significantly the 
overall burden of parasites in animals. Another interes-
ting action of the V. persica extract was its incremental 
effects on NO production. NO production by macro-
phages is a known mechanism for removing intracellu-
lar pathogens such as L. major. Various studies demons-
trated the significant antileishmanial activity of NO in 
mice macrophages (62, 63). In animals infected with 
these pathogens, NO production is decreased naturally 
because of amastigote activities (64, 65). Thus, restora-
tion of NO production by plant extracts can be benefi-
cial in diminishing the parasite burden. 
In conclusion, our findings revealed the promising 
potential of V. persica extract as an ideal candidate in 
treatment of CL caused by L. major. However, additio-
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nal investigations need to be carried out in animal mo-
dels and humans to confirm the efficacy and the exact 
mechanism of action of this attractive natural product.
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